Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "Type-2"

207 News Found

American Diabetes Association acknowledges Breath Well-being diabetes reversal programme
News | October 13, 2021

American Diabetes Association acknowledges Breath Well-being diabetes reversal programme

BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes


Twin Health raises US $ 140 million in Series C funding
Startup | October 07, 2021

Twin Health raises US $ 140 million in Series C funding

The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service


WHO new Essential Medicines Lists focus on diabetes and cancer
Public Health | September 30, 2021

WHO new Essential Medicines Lists focus on diabetes and cancer

The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all


Bal Pharma ramps up API capacity of Gliclazide
News | September 28, 2021

Bal Pharma ramps up API capacity of Gliclazide

In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report


Machine Learning to understand and prevent disease
Digitisation | September 17, 2021

Machine Learning to understand and prevent disease

Barbara Engelhardt moves her computational and statistics lab to Gladstone


Medical institutes urge action on Front-of-Pack labels (FOPL) to address India’s health crisis
Public Health | September 14, 2021

Medical institutes urge action on Front-of-Pack labels (FOPL) to address India’s health crisis

Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor


Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
Biotech | August 31, 2021

Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis

Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old


US FDA approves Jardiance to treat adults living with heart failure with a reduced ejection fraction
Drug Approval | August 20, 2021

US FDA approves Jardiance to treat adults living with heart failure with a reduced ejection fraction

New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US


AstraZeneca-Sputnik V combination demonstrates high immunogenicity profile: RDIF
Biotech | August 20, 2021

AstraZeneca-Sputnik V combination demonstrates high immunogenicity profile: RDIF

Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases


Semglee approval to provide huge opportunities in the US insulin biosimilar market
Biotech | August 19, 2021

Semglee approval to provide huge opportunities in the US insulin biosimilar market

FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.